Skip to main content
SpringerLink
Log in

New oral anticoagulants versus vitamin K antagonists for treatment of acute venous thromboembolism: do they really increase the incidence of myocardial infarction?

  • CE-COMMENTARY
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Cushman M, Tsai AW, White RH, Heckbert SR, Rosamond WD, Enright P, Folsom AR (2004) Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 117(1):19–25. doi:10.1016/j.amjmed.2004.01.018

    Article  PubMed  Google Scholar 

  2. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd (1999) Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 159(5):445–453

    Article  CAS  PubMed  Google Scholar 

  3. Carrier M, Le Gal G, Wells PS, Rodger MA (2010) Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med 152(9):578–589. doi:10.1059/0003-4819-152-9-201005040-00008

    Article  PubMed  Google Scholar 

  4. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ, Group R-CS (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361(24):2342–2352. doi:10.1056/NEJMoa0906598

    Article  CAS  PubMed  Google Scholar 

  5. Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, Christiansen AV, Friedman J, Le Maulf F, Peter N, Kearon C, Investigators R-CIT (2014) Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 129(7):764–772. doi:10.1161/CIRCULATIONAHA.113.004450

    Article  CAS  PubMed  Google Scholar 

  6. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI, Investigators A (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369(9):799–808. doi:10.1056/NEJMoa1302507

    Article  CAS  PubMed  Google Scholar 

  7. Fiessinger JN, Huisman MV, Davidson BL, Bounameaux H, Francis CW, Eriksson H, Lundstrom T, Berkowitz SD, Nystrom P, Thorsen M, Ginsberg JS, Investigators TTS (2005) Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 293(6):681–689. doi:10.1001/jama.293.6.681

    Article  CAS  PubMed  Google Scholar 

  8. Investigators E, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363(26):2499–2510. doi:10.1056/NEJMoa1007903

    Article  Google Scholar 

  9. Investigators E-P, Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366(14):1287–1297. doi:10.1056/NEJMoa1113572

    Article  Google Scholar 

  10. Hokusai VTEI, Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369(15):1406–1415. doi:10.1056/NEJMoa1306638

    Article  Google Scholar 

  11. Loffredo L, Perri L, Del Ben M, Angelico F, Violi F (2014) New oral anticoagulants for the treatment of acute venous thromboembolism: are they safer than vitamin K antagonists? A meta-analysis of the interventional trials. Intern Emerg Med. doi:10.1007/s11739-014-1171-7

    PubMed  Google Scholar 

  12. Fox BD, Kahn SR, Langleben D, Eisenberg MJ, Shimony A (2012) Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ 345:e7498. doi:10.1136/bmj.e7498

    Article  PubMed Central  PubMed  Google Scholar 

  13. Kang N, Sobieraj DM (2014) Indirect treatment comparison of new oral anticoagulants for the treatment of acute venous thromboembolism. Thromb Res 133(6):1145–1151. doi:10.1016/j.thromres.2014.03.035

    Article  CAS  PubMed  Google Scholar 

  14. Mantha S, Ansell J (2014) Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism. J Thromb Thrombolysis. doi:10.1007/s11239-014-1102-5

    PubMed  Google Scholar 

  15. van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV (2014) Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 12(3):320–328. doi:10.1111/jth.12485

    Article  PubMed  Google Scholar 

  16. Gomez-Outes A, Terleira-Fernandez AI, Lecumberri R, Suarez-Gea ML, Vargas-Castrillon E (2014) Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis. Thromb Res 134(4):774–782. doi:10.1016/j.thromres.2014.06.020

    Article  CAS  PubMed  Google Scholar 

  17. Castellucci LA, Cameron C, Le Gal G, Rodger MA, Coyle D, Wells PS, Clifford T, Gandara E, Wells G, Carrier M (2014) Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis. JAMA 312(11):1122–1135. doi:10.1001/jama.2014.10538

    Article  CAS  PubMed  Google Scholar 

  18. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L, Randomized Evaluation of Long-Term Anticoagulation Therapy I (2010) Newly identified events in the RE-LY trial. N Engl J Med 363(19):1875–1876. doi:10.1056/NEJMc1007378

    Article  CAS  PubMed  Google Scholar 

  19. Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, Eikelboom J, Brueckmann M, Yusuf S, Connolly SJ (2012) Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation 125(5):669–676. doi:10.1161/CIRCULATIONAHA.111.055970

    Article  CAS  PubMed  Google Scholar 

  20. Artang R, Rome E, Nielsen JD, Vidaillet HJ (2013) Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors. Am J Cardiol 112(12):1973–1979. doi:10.1016/j.amjcard.2013.08.027

    Article  CAS  PubMed  Google Scholar 

  21. Mak KH (2012) Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. BMJ open 2(5). doi:10.1136/bmjopen-2012-001592

  22. Loffredo L, Perri L, Violi F (2014) Myocardial infarction and atrial fibrillation: different impact of anti-IIa vs anti-Xa new oral anticoagulants: a meta-analysis of the interventional trials. Int J Cardiol 178C:8–9. doi:10.1016/j.ijcard.2014.10.124

    Google Scholar 

  23. Providencia R, Grove EL, Husted S, Barra S, Boveda S, Morais J (2014) A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens. Thromb Res 134(6):1253–1264. doi:10.1016/j.thromres.2014.10.002

    Article  CAS  Google Scholar 

  24. Loke YK, Pradhan S, Yeong JK, Kwok CS (2014) Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison. Br J Clin Pharmacol 78(4):707–717. doi:10.1111/bcp.12376

    Article  CAS  PubMed  Google Scholar 

  25. Adam SS, McDuffie JR, Ortel TL, Williams JW Jr (2012) Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med 157(11):796–807. doi:10.7326/0003-4819-157-10-201211200-00532

    Article  PubMed  Google Scholar 

  26. Wallentin L, Wilcox RG, Weaver WD, Emanuelsson H, Goodvin A, Nystrom P, Bylock A, Investigators E (2003) Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 362(9386):789–797. doi:10.1016/S0140-6736(03)14287-0

    Article  CAS  PubMed  Google Scholar 

  27. Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, Tijssen JG, Van de Werf F, Wallentin L, Investigators R-D (2011) Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 32(22):2781–2789. doi:10.1093/eurheartj/ehr113

    Article  CAS  PubMed  Google Scholar 

  28. Committee AS, Investigators Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, Fox KA, Goodman SG, Harrington RA, Huber K, Husted S, Lewis BS, Lopez-Sendon J, Mohan P, Montalescot G, Ruda M, Ruzyllo W, Verheugt F, Wallentin L (2009) Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 119(22):2877–2885. doi:10.1161/CIRCULATIONAHA.108.832139

    Article  Google Scholar 

  29. Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan ES, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson CM, Group AA-Ts (2009) Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 374(9683):29–38. doi:10.1016/S0140-6736(09)60738-8

    Article  CAS  PubMed  Google Scholar 

  30. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R, White H, Ruda M, Geraldes M, Lawrence J, Harrington RA, Wallentin L (2011) Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 365(8):699–708. doi:10.1056/NEJMoa1105819

    Article  CAS  PubMed  Google Scholar 

  31. Cavender MA, Gibson CM, Braunwald E, Wiviott SD, Murphy SA, Toda Kato E, Plotnikov AN, Amuchastegui M, Oude Ophuis T, van Hessen M, Mega JL (2014) The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2—TIMI 51 trial. Eur Heart J Acute Cardiovasc Care. doi:10.1177/2048872614554109

    PubMed  Google Scholar 

  32. Oldgren J, Wallentin L, Alexander JH, James S, Jonelid B, Steg G, Sundstrom J (2013) New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J. doi:10.1093/eurheartj/eht049

    PubMed Central  Google Scholar 

  33. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA (2005) Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365(9458):475–481. doi:10.1016/S0140-6736(05)17864-7

    Article  CAS  PubMed  Google Scholar 

  34. Levesque LE, Brophy JM, Zhang B (2005) The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 142(7):481–489

    Article  CAS  PubMed  Google Scholar 

  35. Larsen TB, Rasmussen LH, Skjoth F, Due KM, Callreus T, Rosenzweig M, Lip GY (2013) Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 61(22):2264–2273. doi:10.1016/j.jacc.2013.03.020

    Article  CAS  PubMed  Google Scholar 

  36. Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, Sheu TC, Mott K, Goulding MR, Houstoun M, MaCurdy TE, Worrall C, Kelman JA (2014) Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for non-valvular atrial fibrillation. Circulation. doi:10.1161/CIRCULATIONAHA.114.012061

    PubMed  Google Scholar 

  37. Clemens A, Fraessdorf M, Friedman J (2013) Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment. Vasc Health Risk Manag 9:599–615. doi:10.2147/VHRM.S49830

    Article  PubMed Central  PubMed  Google Scholar 

  38. Douxfils J, Buckinx F, Mullier F, Minet V, Rabenda V, Reginster JY, Hainaut P, Bruyere O, Dogne JM (2014) Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 3(3):e000515. doi:10.1161/JAHA.113.000515

    Article  PubMed Central  PubMed  Google Scholar 

  39. Lip GY, Lane DA (2010) Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? Am J Med 123(9):785–789. doi:10.1016/j.amjmed.2010.01.031

    Article  CAS  PubMed  Google Scholar 

  40. Dale B, Eikelboom JW, Weitz JI, Young E, Paikin JS, Coppens M, Whitlock RP, Connolly SJ, Ginsberg JS, Hirsh J (2013) Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction? J Thromb Thrombolysis 35(2):295–301. doi:10.1007/s11239-012-0857-9

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

Dr. Aaron Liew perceives no conflict of interest with this manuscript but has previously received educational and research support from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, Daichii Sankyo, Merck Sharp & Dohme, Novo Nordisk, Novartis, Sanofi-Aventis, and Medtronic.   Dr. Siavash Piran has declared no conflict of interest. Dr. James Douketis perceives no conflict of interest with this manuscript but has served as a Consultant/advisory board participant for Actelion, AGEN Biomedical, Astra-Zeneca, Bayer, Biotie, Bristol Meyers Squibb, Boehringer Ingelheim, Pfizer, Sanofi, and The Medicines Co.

Author information

Authors and Affiliations

  1. Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK

    Aaron Liew

  2. Department of Medicine, St. Joseph’s Healthcare, McMaster University, F-544, 50 Charlton Ave East, Hamilton, ON, L8N 4A6, Canada

    Siavash Piran & James Douketis

Authors
  1. Aaron Liew
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Siavash Piran
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James Douketis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James Douketis.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liew, A., Piran, S. & Douketis, J. New oral anticoagulants versus vitamin K antagonists for treatment of acute venous thromboembolism: do they really increase the incidence of myocardial infarction?. Intern Emerg Med 10, 493–498 (2015). https://doi.org/10.1007/s11739-015-1224-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11739-015-1224-6

Keywords

Search

Navigation